Učitavanje...
Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
The introduction of chemoimmunotherapy and more recently the implementation of novel agents into first-line and relapse treatment have substantially improved treatment outcomes in patients with chronic lymphocytic leukaemia (CLL). With longer progression-free survival and more frequently observed de...
Spremljeno u:
| Izdano u: | Hemasphere |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wolters Kluwer Health
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6919470/ https://ncbi.nlm.nih.gov/pubmed/31942542 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000287 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|